Biohaven Ltd.
Market Cap
$948.55M
P/E Ratio
-1.31
EPS
$-6.86
Dividend Yield
0.00%
52-Week Range
$7.48 — $31.18
Volume
1.54M
Avg Volume
2.71M
Beta
3.53
P/E (TTM)
-1.31
Forward P/E
—
PEG Ratio
-0.19
P/S (TTM)
0.00
P/B (TTM)
22.90
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
-6.89%
ROA (TTM)
-1.64%
ROIC
—
Gross Margin
0.00%
Operating Margin
0.00%
Net Margin
—
Debt/Equity
5.36
Current Ratio
3.18
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
-0.40%
EPS Growth (5Y)
-0.26%
Sales Growth (3Y)
+0.00%
Sales Growth (5Y)
+0.00%
EPS Est (This Year)
$-3.13
EPS Est (Next Year)
$-2.29
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$2.66
Price Target Range
Consensus Target: $22.50(151.1% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
0
Outstanding Shares
105.87M
Float
84.69M
Free Float %
80.00%
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
NYSE
IPO Date
2022-09-23
Employees
256
CEO
Vladimir Coric
Index Membership
—
Website
https://www.biohaven.com
Biohaven Ltd. (BHVN) is a healthcare company in the biotechnology industry listed on the NYSE. With a market capitalization of $948.55M, a P/E ratio of -1.31, BHVN is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare BHVN against other stocks using dozens of fundamental and technical filters.
CYBN
Cybin Inc.
$8.28
+1.22%
$413.02M
FRX.TO
Fennec Pharmaceuticals Inc.
$10.36
+1.77%
$285.42M
BTX
BlackRock Technology and Private Equity Term Trust
$6.53
+0.69%
$762.12M
VKTX
Viking Therapeutics, Inc.
$33.92
+1.10%
$3.92B
STOK
Stoke Therapeutics, Inc.
$33.19
+7.00%
$1.96B
SNDX
Syndax Pharmaceuticals, Inc.
$24.00
+1.48%
$2.12B
Biohaven Ltd. (BHVN) has a trailing twelve-month (TTM) P/E ratio of -1.31. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Biohaven Ltd. (BHVN) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Biohaven Ltd. (BHVN) has a market capitalization of $948.55 million, classifying it as a small-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.